Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/7714
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDimitriadis, E.en
dc.contributor.authorTrangas, T.en
dc.contributor.authorMilatos, S.en
dc.contributor.authorFoukas, P. G.en
dc.contributor.authorGioulbasanis, I.en
dc.contributor.authorCourtis, N.en
dc.contributor.authorNielsen, F. C.en
dc.contributor.authorPandis, N.en
dc.contributor.authorDafni, U.en
dc.contributor.authorBardi, G.en
dc.contributor.authorIoannidis, P.en
dc.date.accessioned2015-11-24T16:33:48Z-
dc.date.available2015-11-24T16:33:48Z-
dc.identifier.issn0020-7136-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/7714-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectColonic Neoplasms/*metabolismen
dc.subjectFemaleen
dc.subjectGene Expressionen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectIntestinal Mucosa/metabolismen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPrognosisen
dc.subjectRNA, Messenger/metabolismen
dc.subjectRNA-Binding Proteins/*metabolismen
dc.subjectReverse Transcen
dc.titleExpression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical outcome in colon canceren
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1002/ijc.22716-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17415713-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1002/ijc.22716/asset/22716_ftp.pdf?v=1&t=h2a39dtf&s=4e5cfbc0e464f8835c0d1e17d5c0ada5d1ebfebd-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιώνel
heal.publicationDate2007-
heal.abstractThe oncofetal CRD-BP/IMP1 RNA binding protein regulates posttranscriptionally a handful of RNA transcripts, implicated in cell adhesion and invadopodia formation and was recently identified as a target of the beta-catenin/Tcf transcription factor that is constitutively activated in colorectal carcinomas (CRCs). The expression of CRD-BP/IMP1 was studied in normal adult intestines and CRCs. In normal mucosa, CRD-BP/IMP1 immunoreactivity was observed in few scattered cells located predominantly at or near the bottom of the crypts, whereas in CRCs the protein was detectable in tumor cells of 50% of the specimens analyzed. CRD-BP/IMP1 mRNA expression was measured by qRT-PCR in 78 CRCs. Thirty-two (41%) of the specimens were negative or had negligible expression, whereas the remaining forty-six (59%) expressed a wide range of CRD-BP/IMP1 mRNA levels. CRD-BP/IMP1 mRNA expression correlated with that of the putative stem/progenitor cell marker Musashi-1 mRNA (p = 0. 035). CRD-BP/IMP1 positive tumors metastasized and/or recurred more frequently (p = 0.001) and its expression defined a group of patients with shorter survival (p = 0.014). Furthermore, in a multivariate analysis CRD-BP/IMP1 expression was found to be an independent predictor of survival (p = 0.015). For stage I & II patients, the differences in metastasis/recurrence and survival rates remained significant (p = 0.001 and 0.033, respectively). These findings indicate that CRD-BP/IMP1 positive tumors exhibit early disease dissemination and unfavorable prognosis.en
heal.journalNameInt J Canceren
heal.journalTypepeer reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Dimitriadis-2007-Expression of oncofe.pdf358.81 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons